1272 Ovarian cancer patients with minimal residual disease: TPA, CA-125 and TATI sensitivity

1995 ◽  
Vol 31 ◽  
pp. S265
Author(s):  
Z. Stanojević ◽  
M. Milutinović ◽  
N. Potic Zećevic ◽  
S. Radić ◽  
S. Filipović
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Minimal Residual Disease ◽  
Residual Disease ◽  
Ca 125 ◽  
Minimal Residual

Intraperitoneal (ip) Cisplatin-Mitoxantrone-Interferon-α2b in Ovarian Cancer Patients with Minimal Residual Disease

1993 ◽  
Vol 50 (1) ◽  
pp. 60-67 ◽  
Author(s):  
G. Frasci ◽  
A. Tortoriello ◽  
G. Facchini ◽  
S. Conforti ◽  
A. Cardone ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Minimal Residual Disease ◽  
Residual Disease ◽  
Interferon Α2b ◽  
Minimal Residual

The impact of whole-abdomen radiotherapy on survival in advanced ovarian cancer patients with minimal residual disease after chemotherapy

1990 ◽  
Vol 39 (2) ◽  
pp. 150-154 ◽  
Author(s):  
Giorgio Bolis ◽  
Flavia Zanaboni ◽  
Paolo Vanoli ◽  
Antonio Russo ◽  
Massimo Franchi ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Minimal Residual Disease ◽  
Residual Disease ◽  
Advanced Ovarian Cancer ◽  
The Impact ◽  
Minimal Residual

Ca-125 Monitoring during Chemotherapy for Ovarian Cancer

1986 ◽  
Vol 1 (3) ◽  
pp. 121-128 ◽  
Author(s):  
Andrea Martoni ◽  
Antonia Bellucco ◽  
Alberto Marabini ◽  
Camillo Orlandi ◽  
Livia Platé ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Minimal Residual Disease ◽  
Prognostic Value ◽  
Progressive Disease ◽  
Residual Disease ◽  
Ca 125 ◽  
Response To Chemotherapy ◽  
Minimal Residual ◽  
Active Disease

Serum CA-125 was determind in 60 patients with variously extended ovarian cancer and monitored during and after chemotherapy. The study indicates that: 1) prechemotherapy CA-125 shows the presence of an active disease with an accuracy > 85%. The antigen is elevated in 97% of patients with > 2 cm disease, but sensitivity is low (67%) in patients with minimal residual disease (< 2 cm); 2) changes in CA-125 correspond well with the response to chemotherapy. CA-125 becomes negative in every patient having clinical CR and increases in every patient with progressive disease. These changes can indicate the type of response some months ahead of time; 3) CA-125 indicates in advance the recurrence of the disease after an objective remission: 4) In the conditions studied CA-125 basal levels do not seem to have prognostic value as regarding either response or survival.

Sign in / Sign up

Export Citation Format

Share Document